Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.34 |
| ▸ | RAF1 | P04049 | 8/20 | 0.34 |
| ▸ | BRAF | P15056 | 8/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.32 |
| ▸ | TNKS | O95271 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25407982 | 0.85 | TLR9 (0.40) | L3MBTL1PIM1TLR9TLR8TLR7 | |
| SCHEMBL25408149 | 0.84 | L3MBTL1 (0.36) | L3MBTL1PIM1PIM2RAF1BRAF | |
| SCHEMBL25408695 | 0.83 | SMO (0.38) | RAF1BRAF | |
| SCHEMBL28973255 | 0.81 | HRH3 (0.37) | RAF1BRAF | |
| SCHEMBL25281709 | 0.80 | TLR9 (0.39) | L3MBTL1TLR9TLR8TLR7 | |
| SCHEMBL25408410 | 0.78 | L3MBTL1 (0.43) | L3MBTL1RAF1BRAFTLR9TLR8 | |
| SCHEMBL26309282 | 0.78 | CKS1B (0.47) | TLR9TLR8TLR7SUV39H2SYK | |
| SCHEMBL25408196 | 0.78 | PIM1 (0.32) | PIM1PIM2 | |
| SCHEMBL25276459 | 0.72 | TLR9 (0.35) | L3MBTL1RAF1BRAFTLR9TLR8 | |
| SCHEMBL25229470 | 0.71 | L3MBTL1 (0.36) | L3MBTL1RAF1BRAFTLR8SUV39H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279001-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230279001-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279001-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | SSB, CNKSR1, UACA | L3MBTL1 4110/4885PIM1 1382/4885PIM2 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.